Lilly claims the weight-loss drug reduced the risk of heart failure by 38 per cent in trials
Trial results show that Eli Lilly’s weight-loss drug Zepbound reduces the risk of hospitalisation, death and other outcomes for adults with obesity and a common type of heart failure, the company said on Thursday, continuing to gather evidence of the drug’s broader health benefits.
POPULAR POSTS
Putin may discuss Ukraine peace deal with Trump
November 22, 2024
Spain’s vice-president Ribera blames floods on climate change
November 22, 2024
Storm lashes northwestern US, killing two people
November 22, 2024
Iceland volcano erupts for tenth time in three years
November 22, 2024
LIVE STREAM